What is your preferred adjuvant regimen for an optimally cytoreduced, stage III low grade serous ovarian carcinoma?

My decision for adjuvant cytotoxic chemotherapy following initial/primary optimal debulking for advanced Stage III Disease is based upon both personal experiences as well as with literature guidance.

The initial guiding issues that I use are age and residual disease at completion of therapy. I am answering this question with the assumption that the patient has not had neoadjuvant therapy prior to surgery. In this setting, neoadjuvant chemotherapy has a very low response rate, of only 4% with a CR and 88% with stable disease. The remainder had progressed (1).

If I am successful in obtaining R0 disease, and my patient is elderly, based upon her comorbidities, I may bypass chemotherapy and proceed with Endocrine therapy alone (an AI). I monitor ...